The volume of healthcare deals has increased in 2022, driven in large part by private equity, according to a new PwC report. But deal values have been declining, a trend that is expected to continue into 2023.
There was a total of 188 deals in the first half of the year. Healthcare consumer engagement accounted for 17 deals amounting to $321 million, according to Rock Health.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Konica views the deal as a "stepping stone" marking its debut as a player in the space and plans to bring Ambry’s products to Japan and then to Europe.
An examination of the advantages and drawbacks of traditional investment models: Investing in health IT partner companies and partnering with other organization on joint ventures.
Revenue for the second opinion service Best Doctors added up to $92 million last year and is projected to be $100 million this year.
Despite the slowdown in private equity markets seen elsewhere in the early part of 2017, investment levels in digital health in 2017 to date are tracking on par with 2015 and 2016.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Remote monitoring was a dominant theme among digital health companies closing funding rounds this week.
I would love to see StartUp Health do a report dedicated to life science companies with an IT component in 2017.
New investors, including iSeed Ventures and DeNA Ventures, took part in the funding round.
Also, China healthcare spending has soared to $3.9 billion in overseas acquisitions across pharma, biotech and healthcare through the first half of the year and Amicus acquired Miamed.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.
Underscoring the hot investment prospects of cancer immunotherapy, Juno Therapeutics has secured additional funding from investors to close its Series A at $176 million, according to a company statement. The company is developing two immunotherapy platforms to treat hematologic and solid tumor cancers and reduce the toxicity associated with chemotherapeutics. The completion of the A […]
Between Pfizer and AstraZeneca deal rumors followed by a strategic portfolio exchange by GlaxoSmithKline and Novartis and an offer for Allergan this week, it feels like a deal frenzy is underway. When you look at the numbers from the first quarter, it seems a little like 2008-2009 when megadeals led to significant consolidation in the […]
On the surface, the first quarter venture capital funding report by National Venture Capital Association and PriceWaterhouseCoopers looks like another downward trend for venture capital deal flow in the life science sector. But if you dig a little deeper there are some positive trends, too. Biotechnology companies attracted $1.1 billion across 112 deals, putting the […]
As pharmaceutical companies look for ways to add value to their drugs to solve problems like adherence, many see digital health as an important part of that strategy. Respiratory drug developer Opko Health (NYSE: OPK) has acquired an Israeli medical device startup, Inspiro Medical, with a digital dry powder inhaler under development, according to a […]
I am late to the party but it’s official. I love Shark Tank. My favorite pitch so far has been the farmer with the tree guard for young trees. Johnny George’s Tree T Pee is a real product: it serves a purpose and it saves money for businesses. The negotiations were interesting last week, but […]